Martin Balada and Kateřina Podrazilová from the Association of Health Insurance Companies of the Czech Republic (SZP ČR) give a thorough insight into the current dialogues surrounding pricing and reimbursement, set to deeply impact access to highly innovative and orphan drugs in the country. Furthermore, they evaluate the uniqueness of the Czech multi-insurance structure and reflect upon the complexity that lies in finding the balance between accessibility, efficacy, and sustainability in the Czech Republic.
Our vision for the future is to keep looking for solutions to finance new drugs that can add value to the Czech healthcare system and, hence, save and improve the lives of more patients.
